Ron Gibson, MD, PhD

He is committed to high-quality, multidisciplinary patient care, small group teaching, research and the acquisition of new knowledge. His primary research focus is on early events in the pathogenesis of lung disease in CF, with a focus on the risk factors for and the treatment of Pseudomonas aeruginosa airway infections in young children with cystic fibrosis (CF). As a co–principal investigator of the university’s CF Translational Therapeutic Development Center, he has been lead and co-investigator for several phase I to phase III clinical trials involving novel antimicrobial agents, anti-inflammatory compounds and modulators of ion transport. Dr. Gibson is also director of the clinical core of the university’s CF research development program with the goal of catalyzing collaborations between local basic and clinical investigators.